Cholangiocarcinoma, Fibrolamellar Carcinoma, Hepatic Angiosarcomas, Hepatic Carcinosarcomas, Hepatic Cystadenoma, Hepatic Epithelioid Hemangioendothelioma, Hepatic Leiomyosarcomas, Hepatic Neuroendocrine Carcinoma, Hepatoblastoma, Hepatocholangiocarcinoma
Conditions
Keywords
rare primary liver cancers, LIVER, HEPATIC, COHORT, RISK FACTORS
Brief summary
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
Detailed description
The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.
Interventions
None listed
Sponsors
Société Nationale Française de Gastroentérologie
Federation Francophone de Cancerologie Digestive
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age or older, * with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma * diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort * for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.
Exclusion criteria
* without social security * No access to tumor block
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of the clinical, histological and radiological characteristics of various rare primary liver cancers | up to 5 years from the date of diagnosis | Description of the clinical, histological and radiological characteristics of various rare primary liver cancers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival (for non-metastatic patients) | up to 5 years from diagnosis | Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news |
| Progression-free survival (for metastatic patients) | up to 5 years from diagnosis | Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news. |
| Overall survival | up to 5 years from diagnosis | Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news. |
Countries
France
Contacts
Primary Contactlila gaba
Outcome results
None listed